Mode
Text Size
Log in / Sign up
N/A N=463 Randomized Diagnostic

A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients

MRSA Colonization

Enrolled (actual)
463
Serious AEs
0.0%
Results posted
Nov 2012
Primary outcome: Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
nucleic acid amplification of nasal swab; nasal swab culture (Device); Nasal swab culture (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Sep 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays
96.6
PRIMARY
Completion of Screening Protocol in Both Trial Arms
73.7; 9.6
PRIMARY
Discontinuation of Contact Precautions in Both Trial Arms
55.2; 86.7
SECONDARY
Number of Subjects With a Single Positive PCR Result and at Least 1 Positive Culture Assay
62
SECONDARY
Sensitivity of First PCR Assay
93.9
SECONDARY
Specificity of First PCR Assay.
92.0
SECONDARY
Rate of Recolonization or Documented Infection With MRSA
8

Summary

Methicillin-resistant Staphylococcus aureus (MRSA) is endemic in hospital settings. Colonization with MRSA puts patients at increased risk for invasive infections, and MRSA infections have been associated with high costs and adverse clinic outcomes. Patients can clear MRSA spontaneously. Improved approaches for identifying patients who are no longer colonized are needed; we hypothesize that more sensitive nucleic acid amplification can be used to improve identification of patients who are no longer colonized.

Eligibility Criteria

Inclusion Criteria

  • age > 18
  • last positive MRSA culture greater than 3 months old
  • admitted to hospital

Exclusion Criteria

  • age < 18
  • last positive MRSA culture less than or equal to 3 months old
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01234831). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search